Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NVAX
- Price
- 8.65
- Stock movement down
- -0.05 (-0.57%)
- Company name
- Novavax Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.41B
- Ent value
- 2.47B
- Price/Sales
- 1.32
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 4.11
- Forward P/E
- 31.36
- PEG
- -
- EPS growth
- -25.88%
- 1 year return (CAGR)
- 5.75%
- 3 year return (CAGR)
- -4.01%
- 5 year return (CAGR)
- -51.30%
- 10 year return (CAGR)
- -21.14%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NVAX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 4.11 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 2.34 |
| EV to EBITDA | 4.12 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.32 |
| Price to Book | - |
| EV to Sales | 2.32 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 162.50M |
| EPS (TTM) | 2.10 |
| FCF per share (TTM) | -2.37 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.06B |
| Gross profit (TTM) | 978.15M |
| Operating income (TTM) | 312.08M |
| Net income (TTM) | 341.75M |
| EPS (TTM) | 2.10 |
| EPS (1y forward) | 0.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 91.87% |
| Operating margin (TTM) | 29.31% |
| Profit margin (TTM) | 32.10% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 268.02M |
| Net receivables | 34.17M |
| Total current assets | 974.59M |
| Goodwill | 113.08M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 72.99M |
| Total assets | 1.18B |
| Accounts payable | 15.23M |
| Short/Current long term debt | 251.14M |
| Total current liabilities | 429.87M |
| Total liabilities | 1.34B |
| Shareholder's equity | -156.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -378.32M |
| Capital expenditures (TTM) | 5.74M |
| Free cash flow (TTM) | -384.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | 28.96% |
| Return on Invested Capital | -225.37% |
| Cash Return on Invested Capital | 253.28% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.52 |
| Daily high | 8.85 |
| Daily low | 8.49 |
| Daily Volume | 2.27M |
| All-time high | 319.93 |
| 1y analyst estimate | 12.89 |
| Beta | 2.58 |
| EPS (TTM) | 2.10 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| NVAX | S&P500 | |
| Current price drop from All-time high | -97.30% | -1.82% |
| Highest price drop | -98.82% | -56.47% |
| Date of highest drop | 5 Feb 2024 | 9 Mar 2009 |
| Avg drop from high | -70.44% | -10.84% |
| Avg time to new high | 205 days | 12 days |
| Max time to new high | 4866 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.41B
Marketcap category
Small-cap
Description
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Employees
952
Website
Investor relations
SEC filings
CEO
Stanley Erck
Country
USA
City
Gaithersburg
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page